Cargando…
Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction
BACKGROUND: Heart failure with ejection fraction (HFpEF) is a syndrome resulting from several co-morbidities in which specific mediators are unknown. The platelet proteome responds to disease processes. We hypothesize that the platelet proteome will change composition in patients with HFpEF and may...
Autores principales: | Raphael, Roseanne, Purushotham, Diana, Gastonguay, Courtney, Chesnik, Marla A., Kwok, Wai-Meng, Wu, Hsiang-En, Shah, Sanjiv J., Mirza, Shama P., Strande, Jennifer L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719542/ https://www.ncbi.nlm.nih.gov/pubmed/26792056 http://dx.doi.org/10.1186/s12967-016-0774-3 |
Ejemplares similares
-
Post-translational regulation of COX2 activity by FYN in prostate cancer cells
por: Alexanian, Anna, et al.
Publicado: (2014) -
The Cardiomyocyte in Heart Failure with Preserved Ejection Fraction—Victim of Its Environment?
por: Rocca, Angela, et al.
Publicado: (2022) -
Aortic stiffening precedes onset of heart failure with preserved ejection fraction in patients with asymptomatic diastolic dysfunction
por: Karagodin, Ilya, et al.
Publicado: (2017) -
Unveiling Human Proteome Signatures of Heart Failure with Preserved Ejection Fraction
por: Sebastião, Maria J., et al.
Publicado: (2022) -
The future of heart failure with preserved ejection fraction: Deep phenotyping for targeted therapeutics
por: Heinzel, Frank R., et al.
Publicado: (2022)